Przejdź do zawartości
Merck

The transcriptional regulator ADNP links the BAF (SWI/SNF) complexes with autism.

American journal of medical genetics. Part C, Seminars in medical genetics (2014-08-30)
Geert Vandeweyer, Céline Helsmoortel, Anke Van Dijck, Anneke T Vulto-van Silfhout, Bradley P Coe, Raphael Bernier, Jennifer Gerdts, Liesbeth Rooms, Jenneke van den Ende, Madhura Bakshi, Meredith Wilson, Ann Nordgren, Laura G Hendon, Omar A Abdulrahman, Corrado Romano, Bert B A de Vries, Tjitske Kleefstra, Evan E Eichler, Nathalie Van der Aa, R Frank Kooy
ABSTRAKT

Mutations in ADNP were recently identified as a frequent cause of syndromic autism, characterized by deficits in social communication and interaction and restricted, repetitive behavioral patterns. Based on its functional domains, ADNP is a presumed transcription factor. The gene interacts closely with the SWI/SNF complex by direct and experimentally verified binding of its C-terminus to three of its core components. A detailed and systematic clinical assessment of the symptoms observed in our patients allows a detailed comparison with the symptoms observed in other SWI/SNF disorders. While the mutational mechanism of the first 10 patients identified suggested a gain of function mechanism, an 11th patient reported here is predicted haploinsufficient. The latter observation may raise hope for therapy, as addition of NAP, a neuroprotective octapeptide named after the first three amino acids of the sequence NAPVSPIQ, has been reported by others to ameliorate some of the cognitive abnormalities observed in a knockout mouse model. It is concluded that detailed clinical and molecular studies on larger cohorts of patients are necessary to establish a better insight in the genotype phenotype correlation and in the mutational mechanism.